Divi’s Labs: Jefferies maintains a Buy on Divi’s Labs with a Target Price of ₹7950, citing strong growth in Custom Synthesis and nutraceuticals, guidance for sustained double-digit INR growth, and ambitions to become a major peptide manufacturer, despite weak generics sales and regulatory uncertainty around key CS projects.

 25 May 2026 09:01 AM

Divi’s Labs: Jefferies maintains a Buy on Divi’s Labs with a Target Price of ₹7950, citing strong growth in Custom Synthesis and nutraceuticals, guidance for sustained double-digit INR growth, and ambitions to become a major peptide manufacturer, despite weak generics sales and regulatory uncertainty around key CS projects.

Divi’s Labs: Kotak Institutional Equities maintains a Sell on Divi’s Labs with a Target Price of ₹5850, citing a Q4 operating miss from softer CSM growth, high ongoing capex intensity, and expensive valuations despite strong client engagement and multiple peptide and CSM projects in the pipeline.

 25 May 2026 09:01 AM

Divi’s Labs: Kotak Institutional Equities maintains a Sell on Divi’s Labs with a Target Price of ₹5850, citing a Q4 operating miss from softer CSM growth, high ongoing capex intensity, and expensive valuations despite strong client engagement and multiple peptide and CSM projects in the pipeline.

Divi's Labs: Says Revenue From Capital Expenditure Is Hard To Forecast Due To Customer Schedules And Regulatory Approvals, With A Two-Year Estimate Being Optimistic. Management Notes That Margin Projections For FY27 Are Challenging, Yet Expected To Stay Stable Given The Current Conditions.

 25 May 2026 08:50 AM

Divi's Labs: Says Revenue From Capital Expenditure Is Hard To Forecast Due To Customer Schedules And Regulatory Approvals, With A Two-Year Estimate Being Optimistic. Management Notes That Margin Projections For FY27 Are Challenging, Yet Expected To Stay Stable Given The Current Conditions.

Divi's Labs: Forecasts Double-Digit Revenue Growth, Predicts Stable Margins Despite Uncertainty.

 25 May 2026 08:50 AM

Divi's Labs: Forecasts Double-Digit Revenue Growth, Predicts Stable Margins Despite Uncertainty.

DIVI'S LAB: Q4 CONS NET PROFIT 7.5B RUPEES VS 6.6B (YOY) || Q4 REVENUE 28.3B RUPEES VS 25.85B (YOY)

 23 May 2026 02:17 PM

DIVI'S LAB: Q4 CONS NET PROFIT 7.5B RUPEES VS 6.6B (YOY) || Q4 REVENUE 28.3B RUPEES VS 25.85B (YOY)

DIVI'S LAB.: Q4 EBITDA 10.7B RUPEES VS 8.86B (YOY) || Q4 EBITDA MARGIN 37.94% VS 34.3% (YOY)

 23 May 2026 02:18 PM

DIVI'S LAB.: Q4 EBITDA 10.7B RUPEES VS 8.86B (YOY) || Q4 EBITDA MARGIN 37.94% VS 34.3% (YOY)